The uncertainty caused by the COVID-19 pandemic has seen over 13% of Americans reporting starting or increasing use of illicit substances as a coping mechanism. The Quit Using Drugs Intervention Trial (QUIT) screening and brief intervention (SBI) reduced risky drug use among low-income primary care clinics patients over 3 months. A new SBI trial, QUIT-Mobile, augments the QUIT intervention by adding mobile phone self-monitoring, weekly automated feedback messages, and dashboards to support telephone coach monitoring of patients’ self-monitoring data during coaching sessions. Reduced in-person clinic capacities due to the COVID-19 pandemic and reduced clinic waiting room times led to expansion of telehealth services, which required the QUIT-Mobile team to adapt from in-person screening in clinic waiting rooms to online clinic visit pre-screening and remote patient recruitment, enrollment and assessment. Patients will be randomized into three groups: QUIT-Mobile, Standard-QUIT, and usual care. All participants will receive brief advice from their Primary Care Provider, a video doctor, and health education resources. Patients in the QUIT or QUIT-Mobile arm will be assigned a health coach to monitor patient responses to questionnaires and lead telephone coaching sessions that use motivational interviewing techniques.The QUIT-Mobile arm will receive self-monitoring text-message surveys on a biweekly basis for 6 weeks and on a weekly basis from 6 weeks to 12 months following the brief intervention. Surveys consist of 10 questions regarding drug and alcohol use and cravings, and quality of life. Automated feedback text-messages will use positive reinforcement hypothesized to enhance and sustain the impacts of the physician brief advice and telephone health coaching. Participants’ experiences will be assessed at 3, 6, and 12-month follow-ups. We hypothesize that those in the QUIT-Mobile group will experience the greatest reduction in drug use.